Exubera Approved

The U.S. Food and Drug Administration announced yesterday that the agency had approved the first inhaled insulin - Exubera - for use in adults with type 1 and type 2 diabetes. The FDA has also required that Pfizer, the drug's manufacturer, conduct a long-term study in 5,000 Exubera patients with type 1 and type 2 diabetes to monitor whether lung function decreases over time. In clinical trials, the drug caused a short term decrease in lung function in some patients.

Find out more about Exubera's approval here.

Comments